Member Info for bbrq648

daft63,
The validation procedures adopted is a phased work for PHA approval process.
Acceptable Paraytec LFD Trial Testing had facilitated for taking part in PHA validation / approval for Phase 2, 2A & 3 Testing. Thus there is little or no risk at all for Paraytec LFD Test to pass this PHA validation and approval process.

For the Phase 3 manufacturing assistance will be required in large scale ( time being minimum 1200 tests). Thus, a manufacturing agreement would be required at this stage. Thus, a JV or Consortium would be required for large scale agreement prior to Phase 3 Testing. Also, LFD Testing Kits, consumables and hardware and software, QA & QC management will also be required in addition to Project Management, Logistic and Procurement.

Furthermore, the current technology is suitable for detection of other viruses, bladder testing and sepsis testing, it would not be prudent to sell Paraytec because of the long term yield that would bring to BRH/ Paraytec Companies as a whole.

Guys & Girls,
Please see excepts from the ODX RNS which clearly states pending approval,
“In addition, the Company still awaits confirmation that a COVID-19 lateral flow antigen test has passed the necessary performance evaluation. Accordingly, there are no COVID-19 lateral flow antigen tests that can be manufactured by Omega, on behalf of the Government, at this time.

As soon as the DHSC has access to a test that has successfully passed performance evaluation, it will be licensed to Omega for manufacture. When the test is ready for production Omega expects to receive purchase orders from the DHSC for these tests and, where appropriate, the Company will make further statements given that these production volumes are expected to result in substantial revenue growth for new financial year.”

What is the big deal?
BRH/ Paraytec is also on the same phase, “Phase 2 & Phase 2A approval process and Phase 3 to follow manufacturing”.

RE: Braveheart Investment Group PLC Historic Prices
Date Open High Low Close Volume
Mar 13, 2021 62.50p 62.00p 60.13p 60.50p 447,390
Mar 12, 2021 64.00p 68.22p 61.08p 62.50p 375,924
Mar 11, 2021 66.00p 69.50p 62.30p 64.00p 708,129
Mar 10, 2021 70.00p 75.00p 65.00p 66.50p 874,836
Mar 9, 2021 66.50p 74.94p 65.12p 72.00p 988,004

The trend in volume is reducing gradually from Mar 9, 2021 onwards with the exception today due to shareholders jumping the ship for quick bucks.
From tomorrow onwards, buys will be more than sells.

The reasons why is given below:
RE: DHSC Protocol for Evaluation of Rapid Diagnostic LFD Testing

The protocol for evaluation of rapid diagnostic LFD Testing criteria are well with the capability of BRH/ Paraytec LFD Tests.

The minor modifications of BRH/ Paraytec LFD Tests made to meet the PHE Porton Down to establish a time-limited SARS-CoV-2 test development and evaluation programme.

BRH/ Paraytec had passed the Phase 1 and patience will be required for the Phase 2 Evaluation Criteria which can be easily met by our 500 LFD Tests currently under progress hence the delay.

However, please note that BRH/ Paraytec LFD Tests will pass Phase 2 with flying colours, as Paraytec and Sheffield University Team headed by Prof. Carl Smythe have worked towards meeting to satisfy and exceed the criteria required for Phase 2 & 2A.

Note:
As per the Prof. Carl Smythe interview with Proactive Investors, he had clearly demonstrated how to achieve the required sensitivity and specificity.

Phase 3 Trials takes a bit of time to test a minimum of 1200 samples and in parallel large scale manufacturing put in place, to quality control the manufacturing products with the help of JV partners or consortium.

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices

Even though we are slightly behind our competitors, our product is best in the world. Hence, buy the BRH share and keep it tugged away and wait till end of April, 2021 and then July, 2021. The dates are as outlined in the 01-Mar-2021 RNS. Credit goes to Trevor Brown (CEO) and his team for guidance to take BRH/ Paraytec in the best interest of shareholders.

Please also note that at present only less than 50% of the shares are currently available for PI and Traders, which is in the order of 18,000,000.
The above figure did not include current PI holding. If we assume the current PI holders have 9 to 10 m, then this leaves only 8 m available shares for purchase. Hence high demand. Best to buy now rather than pay a premium price for this technology & scientifically advanced shares.

Genuine Shareholders please take note and act accordingly.
DYOR.

Watch the day is going to end in BLUE.
From now on BLUE days to commence.
DYOR.

RE: DHSC Protocol for Evaluation of Rapid Diagnostic LFD Testing

The protocol for evaluation of rapid diagnostic LFD Testing criteria are well with the capability of BRH/ Paraytec LFD Tests.

The minor modifications of BRH/ Paraytec LFD Tests made to meet the PHE Porton Down to establish a time-limited SARS-CoV-2 test development and evaluation programme.

BRH/ Paraytec had passed the Phase 1 and patience will be required for the Phase 2 Evaluation Criteria which can be easily met by our 500 LFD Tests currently under progress hence the delay.

However, please note that BRH/ Paraytec LFD Tests will pass Phase 2 with flying colours, as Paraytec and Sheffield University Team headed by Prof. Carl Smythe have worked towards meeting to satisfy and exceed the criteria required for Phase 2 & 2A.

Note:
As per the Prof. Carl Smythe interview with Proactive Investors, he had clearly demonstrated how to achieve the required sensitivity and specificity.

Phase 3 Trials takes a bit of time to test a minimum of 1200 samples and in parallel large scale manufacturing put in place, to quality control the manufacturing products with the help of JV partners or consortium.

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices

Even though we are slightly behind our competitors, our product is best in the world. Hence, buy the BRH share and keep it tugged away and wait till end of April, 2021 and then July, 2021. The dates are as outlined in the 01-Mar-2021 RNS. Credit goes to Trevor Brown (CEO) and his team for guidance to take BRH/ Paraytec in the best interest of shareholders.

Please also note that at present only less than 50% of the shares are currently available for PI and Traders, which is in the order of 18,000,000.
The above figure did not include current PI holding. If we assume the current PI holders have 9 to 10 m, then this leaves only 8 m available shares for purchase. Hence high demand. Best to buy now rather than pay a premium price for this technology & scientifically advanced shares.

Genuine Shareholders please take note and act accordingly.
DYOR.

Casper786,
RE: https://braveheartgroup.co.uk/investor-relations/shareholders/
It states, “We have been notified that the following shareholders have an interest of 3% or more of the total shares in issue:”, but it had included W Rehman with less than 3% (2.88%) included, which needs to be removed.

The share holders having more than 3% of total shares was erroneously uploaded in the Braveheart Investment Group Home/ Investor Relations/ Shareholders for James Sharpe & AG Simpson based on total shares for BRH of 38,297,451.
RNS for James Sharpe was already issued today. RNS for AG Simpson will be issued soon.
As per the case of W Rehman the total share held is now less than 3%, and thus no RNS will be issued regarding his holdings unless as Casper786 suggested that he increased his holdings above 3%.

If this 75p Resistance is broken before Lunch, then this will close above 80p today.
Come on long-standing PI.
Make use of the opportunity.

The market cap of AVCT is at present 595.5 million, whereas BRH is 27.8 million.
Current Status of AVCT: “next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."

Current Status of BRH: Is also the same end of April’ 2021.

For Our key differentiators, please refer to my earlier BB post.
What a value investment here. Make use of this cheap BRH share price.

Jodrell13,
We are in BRH BB, and the total shares in here is approximately 38.4 million only, of which more than 10 million held by Directors & at least 10 million held by long term share holders & nominees Limited.
Thus no automatic buys available.

This BRH/ PARAYTEC COVID-19 LFD TEST key differentiators are as follows:
1) Fastest Test - 2 minutes;
2) Very Sensitive Test;
3) Portable;
4) No Specialist Operator Requirements;
5) Detect Intact COVID-19 Virus ( where as current techniques involve extracting part of the virus and amplify them to detect their presence);
6) Able to test people accurately- Both before symptomatic and afterwards;
7) Able segregate Fall Positive & Fall Negative to further improve testing accuracy; and
8) Matrix Testing (see my earlier posts)

What else can you ask for?
This underlying technology is a unique and can be applied to other viruses and wide variety of different illnesses like Sepsis.

Good Luck to All Genuine BRH Investors!!!!!

Looking forward to another Blue day.
Good Luck to all genuine BRH share holders.

Nina007,
The best way forward is for the NHS track & trace to create a data base.
This data base can be extended by adding various group testing approved by Department of Health & NHS Track and Trace System. Various groups like attendees of football or cricket matches, sport functions and music festivals, etc. For effective crowd management for COVID LFD Testing will help to plan in advance, with emergency plan to test last minute arrivals.
BRH / Paraytec Matrix Testing will help to test 10 rows and 10 columns (10 x 10 Matrix), ie 20 test to identify COVID positive for 100 people, thus saving 80 individual testing.

Furthermore, BRH Testing is carried out in 2 minutes (120 seconds) - Fastest & Accurate Test. Currently Available.

To All Genuine BRH Investors:
In view of the two presentations/ interview by Proactive Investors with Prof. Carl Smythe, and the BRH RNS issued on 01-Mar-2021, it is recommended that this test will pass through the MHRA and CE trade mark approval with flying colours because of the key differentiators of Fastest Testing Time, Increased Accuracy, Sensitivity and Specificity, and Multiplex Testing as explained in my earlier Post. In addition, this is remarkably sensitive and identify relatively low level of detection.

Thus, until the results of this Clinical Trial Testing and MHRA & CE approval come, please don’t sell your shares to make a few pennies instead of losing few sterling pounds(£££££).

To all BRH BB Colleagues:
PROF. Carl Smythe shown in the presentation by sharing his laptop for clarifications raised by false positives and false negatives and how to eliminate the currently available Lateral Flow Device (LFD) Testing, and improvements made in the frequency of detection to separate the position of frequencies to avoid false positives & false negative overlapping, thus improving the accuracy of the BRH LFD testing.

Furthermore, the presentation was explained what the multiplex testing means, i.e., 100 testing is done by carrying out 10 rows testing and 10 column testing, in total 20 tests to uniquely identify the 10 x 10 matrix who are tested positive.
By this method, BRH can save 80 individual tests of competitors.

With the test detection time of 2 minutes in comparison to other 5 to 10 minutes tests and 30 minutes test, the BRH test will become the gold standard LFD Test in the world.
There is no doubt BRH/ PARAYTEC LFD Test is going to be the WORLD GOLD STANDARD LFD TEST in this Globe, in addition to SEPSIS testing.
Hats off to BRH CEO Trevor Brown and his team and PARAYTEC Team and PROF. Carl Smythe and his University of Sheffield Team.

Today’s Interview with Prof. Carl Smythe:
https://www.proactiveinvestors.co.uk/companies/news/943228/paraytec-lead-covid-19-professor-on-sensitivity-and-specificity-of-various-types-of-covid-19-tests-943228.html

For completeness, I am attaching the path of earlier interview with Prof. Carl Smythe:
https://www.proactiveinvestors.co.uk/companies/news/942618/braveheart-investments--paraytec-present-their-operational-covid-19-sample-testing-pipeline-942618.html

Happy reading.

Why BB posters are wasting their time posting on this and each and everyone of genuine investors do their own research and invest.
Please don’t post and waste your time - a piece of advice.
The share price will increase in stages as positive news comes, Clinical Test Results, MHRA acceptance, Obtain CE Mark, Obtain EU & FDA approval, JV arrangement, Fast track Manufacturing, Order book etc.

gold trig,
The £8 Billion is to be awarded to multiple procurement and the Tender Closing Date is 07-Apr-2021. This tender is valid for one year, and additional companies can be added by DHSC if required.
One have to wait till the closing date and DHSC to publish successful vendors.
TB would be aware of this £8 Billions Lateral Flow DPS which is valid for one year, and would take necessary steps to be included as a pre-qualifiers.

Once this is achieved, the orders will pile in and share price will increase.
Wait and see and hold your horse.
Thanks.

The RNS dated 01-Mar-2021 states pending approval by MHRA and CE approval by End of April 2021, are you planning to make a JV with manufacturer or Pharmaceutical major to start production in parallel during the large scale Clinical trial testing to optimise the critical path of large scale production testing and QA approval process in place.
TB please answer.
Thanks.

As stated by by BB post yesterday around 17:01 prior to Prof. Carl Smythe interview with proactive investors, the BRH share price did increased today.
Genuine investors, please hold your shares till large scale clinical trials completed.

Looking forward to a similar rise tomorrow,
Good Luck to all Genuine Investors.

This BRH/ PARAYTEC COVID test kit currently under development can be modified with ease for other new viruses. Today RNS clearly states this from the 120 seconds, which sets a worldwide gold standard test.
Genuine investors please keep calm, and this will make up the losses made today very soon.

Good Luck.